bms-833923
Small moleculeexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00670189)
Timeline
Indications
Mechanism of action
- Smoothened homologANTAGONIST
SMO antagonist
Chemistry & pharmacology
Loading structure…
SMILES
CNCc1ccc(C)c(NC(=O)c2ccc(Nc3nc(-c4ccccc4)c4ccccc4n3)cc2)c1- Mol. weight
- 473.58 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545403 ↗
Also known as
- bms-833923
- bms-833923
- bms-833923
- xl-139
- xl-139
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02100371 | N/A | Feb 1, 2014 | University of Toronto |
| NCT01413906 | Phase 1 | Nov 1, 2011 | Bristol-Myers Squibb |
| NCT01357655 | Phase 2 | Sep 1, 2011 | Bristol-Myers Squibb |
| NCT01218477 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2011 | Bristol-Myers Squibb |
| NCT00927875 | Phase 1 | Feb 1, 2010 | Bristol-Myers Squibb, Exelixis |
| NCT00909402 | Phase 1 | Nov 1, 2009 | Bristol-Myers Squibb, Exelixis |
| NCT00884546 | Phase 1 | Jul 1, 2009 | Bristol-Myers Squibb, Exelixis |
| NCT00670189 | Phase 1 | Jul 1, 2008 | Bristol-Myers Squibb, Exelixis |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 7 | 7 | 2 | 2008 |
| Exelixis | For profit | 4 | 0 | 1 | 2008 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2014 |
3 organizations
Page 1 / 1